Theravance Biopharma (TBPH) Return on Invested Capital (2019 - 2022)
Theravance Biopharma (TBPH) posted quarterly Return on Invested Capital of 0.05% for Q4 2022, little changed year-over-year from 0.05% in Q4 2021, and down 29.86% quarter-over-quarter from 0.04% in Q3 2022.
Theravance Biopharma (TBPH) Return on Invested Capital (2019 - 2022) Analysis & Trends
Theravance Biopharma (TBPH) has reported Return on Invested Capital for 4 consecutive years, with 0.05% the latest figure, recorded in Q4 2022.
- In Q4 2022, Return on Invested Capital changed 0.0% year-over-year to 0.05%; the TTM figure through Dec 2022 stood at 0.05% (changed 0.0% YoY), while the FY2021 annual figure was 0.14%, up 6.0% from the prior year.
- Return on Invested Capital fell to 0.05% in Q4 2022 per TBPH's latest filing, from 0.04% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.04% in Q3 2022 and bottomed at 0.21% in Q3 2020.
- Historically, Return on Invested Capital has averaged 0.09% across 4 years, with a median of 0.07% in 2019.
- Annual changes were most pronounced in 2020 — Return on Invested Capital dropped 13 bps — and 2021, when it rose 15 bps.
- Theravance Biopharma's Return on Invested Capital stood at 0.07% in 2019, then tumbled by 176 bps to 0.2% in 2020, then jumped by 74 bps to 0.05% in 2021, then retreated by 1 bps to 0.05% in 2022.
- Business Quant data shows TBPH's Return on Invested Capital at 0.05% in Q4 2022, 0.04% in Q3 2022, and 0.04% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.04% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.05% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.35% |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -0.05% |
| Sep 30, 2022 | -0.04% |
| Jun 30, 2022 | -0.04% |
| Mar 31, 2022 | -0.05% |
| Dec 31, 2021 | -0.05% |
| Sep 30, 2021 | -0.06% |
| Jun 30, 2021 | -0.08% |
| Mar 31, 2021 | -0.12% |
| Dec 31, 2020 | -0.20% |
| Sep 30, 2020 | -0.21% |
| Jun 30, 2020 | -0.11% |
| Mar 31, 2020 | -0.07% |
| Dec 31, 2019 | -0.07% |
| Sep 30, 2019 | -0.09% |
| Jun 30, 2019 | -0.16% |